144 related articles for article (PubMed ID: 30915540)
1. Study of histopathologic parameters to define the prognosis of stage II colon cancer.
Romiti A; Roberto M; Marchetti P; Di Cerbo A; Falcone R; Campisi G; Ferri M; Balducci G; Ramacciato G; Ruco L; Pilozzi E
Int J Colorectal Dis; 2019 May; 34(5):905-913. PubMed ID: 30915540
[TBL] [Abstract][Full Text] [Related]
2. Tumor budding and poorly-differentiated cluster in prognostication in Stage II colon cancer.
Lee VWK; Chan KF
Pathol Res Pract; 2018 Mar; 214(3):402-407. PubMed ID: 29487008
[TBL] [Abstract][Full Text] [Related]
3. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
4. Poorly Differentiated Clusters Predict Colon Cancer Recurrence: An In-Depth Comparative Analysis of Invasive-Front Prognostic Markers.
Konishi T; Shimada Y; Lee LH; Cavalcanti MS; Hsu M; Smith JJ; Nash GM; Temple LK; Guillem JG; Paty PB; Garcia-Aguilar J; Vakiani E; Gonen M; Shia J; Weiser MR
Am J Surg Pathol; 2018 Jun; 42(6):705-714. PubMed ID: 29624511
[TBL] [Abstract][Full Text] [Related]
5. The presence of poorly differentiated clusters predicts survival in stage II colorectal cancer.
Ammendola S; Turri G; Marconi I; Burato G; Pecori S; Tomezzoli A; Conti C; Pedrazzani C; Barresi V
Virchows Arch; 2021 Feb; 478(2):241-248. PubMed ID: 32577812
[TBL] [Abstract][Full Text] [Related]
6. Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer.
Cienfuegos JA; Martínez P; Baixauli J; Beorlegui C; Rosenstone S; Sola JJ; Rodríguez J; Hernández-Lizoáin JL
Ann Surg Oncol; 2017 Apr; 24(4):1077-1084. PubMed ID: 27624582
[TBL] [Abstract][Full Text] [Related]
7. Histopathological Predictors of Recurrence in Stage III Colon Cancer: Reappraisal of Tumor Deposits and Tumor Budding Using AJCC8 Criteria.
Landau MA; Zhu B; Akwuole FN; Pai RK
Int J Surg Pathol; 2019 Apr; 27(2):147-158. PubMed ID: 29992847
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study.
Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
Int J Colorectal Dis; 2018 Aug; 33(8):1115-1124. PubMed ID: 29785462
[TBL] [Abstract][Full Text] [Related]
9. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in sporadic colon cancer with high-level microsatellite instability.
Oh BY; Huh JW; Park YA; Cho YB; Yun SH; Kim HC; Lee WY; Chun HK
Surgery; 2016 May; 159(5):1372-81. PubMed ID: 26775578
[TBL] [Abstract][Full Text] [Related]
12. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Chouhan H; Sammour T; Thomas ML; Moore JW
J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathological significance of poorly differentiated clusters in colorectal adenocarcinoma].
Yang LL; Gou SQ; Wang JS; Qi Q; Huang WB
Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):276-281. PubMed ID: 30955262
[No Abstract] [Full Text] [Related]
14. Tumor Budding as a Predictive Marker of Relapse and Survival in Patients With Stage II Colon Cancer.
Saito K; Okuyama T; Miyazaki S; Oi H; Mitsui T; Noro T; Takeshita E; Ono Y; Urahashi T; Tajima H; Yoshitomi H
In Vivo; 2022; 36(4):1820-1828. PubMed ID: 35738585
[TBL] [Abstract][Full Text] [Related]
15. Tumor budding as an index to identify high-risk patients with stage II colon cancer.
Nakamura T; Mitomi H; Kanazawa H; Ohkura Y; Watanabe M
Dis Colon Rectum; 2008 May; 51(5):568-72. PubMed ID: 18286339
[TBL] [Abstract][Full Text] [Related]
16. Association Between Obesity and Histological Tumor Budding in Patients With Nonmetastatic Colon Cancer.
Gan T; Schaberg KB; He D; Mansour A; Kapoor H; Wang C; Evers BM; Bocklage TJ
JAMA Netw Open; 2021 Apr; 4(4):e213897. PubMed ID: 33792733
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic impacts of poorly differentiated cluster-based grading system in colorectal carcinoma.
Kim JW; Shin MK; Kim BC
J Korean Med Sci; 2015 Jan; 30(1):16-23. PubMed ID: 25552879
[TBL] [Abstract][Full Text] [Related]
18. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
Pilati C; Taieb J; Balogoun R; Marisa L; de Reyniès A; Laurent-Puig P
Ann Oncol; 2017 May; 28(5):1032-1035. PubMed ID: 28328000
[TBL] [Abstract][Full Text] [Related]
19. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator for adjuvant therapy in colon cancer.
Kumar S; Chang EY; Frankhouse J; Dorsey PB; Lee RG; Johnson N
Arch Surg; 2009 Sep; 144(9):835-40. PubMed ID: 19797108
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
